| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 996 | 2015 |
| IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion V Gocheva, HW Wang, BB Gadea, T Shree, KE Hunter, AL Garfall, ... Genes & development 24 (3), 241-255, 2010 | 880 | 2010 |
| Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients T Condamine, GA Dominguez, JI Youn, AV Kossenkov, S Mony, ... Science immunology 1 (2), aaf8943-aaf8943, 2016 | 705 | 2016 |
| B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma AD Cohen, AL Garfall, EA Stadtmauer, JJ Melenhorst, SF Lacey, ... The Journal of clinical investigation 129 (6), 2210-2221, 2019 | 679 | 2019 |
| Chimeric antigen receptor T cells against CD19 for multiple myeloma AL Garfall, MV Maus, WT Hwang, SF Lacey, YD Mahnke, JJ Melenhorst, ... New England Journal of Medicine 373 (11), 1040-1047, 2015 | 664 | 2015 |
| Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer T Shree, OC Olson, BT Elie, JC Kester, AL Garfall, K Simpson, ... Genes & development 25 (23), 2465-2479, 2011 | 598 | 2011 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 567 | 2022 |
| CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer EM Bange, NA Han, P Wileyto, JY Kim, S Gouma, J Robinson, ... Nature medicine 27 (7), 1280-1289, 2021 | 441 | 2021 |
| Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer S Singhal, PS Bhojnagarwala, S O'Brien, EK Moon, AL Garfall, AS Rao, ... Cancer cell 30 (1), 120-135, 2016 | 400 | 2016 |
| Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis AJ Waxman, S Clasen, WT Hwang, A Garfall, DT Vogl, J Carver, ... JAMA oncology 4 (3), e174519-e174519, 2018 | 237 | 2018 |
| Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study SF Huntington, BM Weiss, DT Vogl, AD Cohen, AL Garfall, PA Mangan, ... The Lancet Haematology 2 (10), e408-e416, 2015 | 209 | 2015 |
| Teclistamab, a B-cell maturation antigen× CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm … SZ Usmani, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, ... The Lancet 398 (10301), 665-674, 2021 | 208 | 2021 |
| Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma AL Garfall, EA Stadtmauer, WT Hwang, SF Lacey, JJ Melenhorst, ... JCI insight 3 (8), 2018 | 204 | 2018 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 199 | 2020 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 171 | 2022 |
| Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma RF Cornell, B Ky, BM Weiss, CN Dahm, DK Gupta, L Du, JR Carver, ... Journal of clinical oncology 37 (22), 1946-1955, 2019 | 164 | 2019 |
| T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma AL Garfall, EK Dancy, AD Cohen, WT Hwang, JA Fraietta, MM Davis, ... Blood advances 3 (19), 2812-2815, 2019 | 162 | 2019 |
| NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines SK Kumar, NS Callander, J Hillengass, M Liedtke, M Baljevic, ... Journal of the National Comprehensive Cancer Network 17 (10), 1154-1165, 2019 | 153 | 2019 |
| NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines NS Callander, M Baljevic, K Adekola, LD Anderson, E Campagnaro, ... Journal of the National Comprehensive Cancer Network 20 (1), 8-19, 2022 | 136 | 2022 |
| Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer KM Bell-McGuinn, AL Garfall, M Bogyo, D Hanahan, JA Joyce Cancer research 67 (15), 7378-7385, 2007 | 133 | 2007 |
